APGE vs. AXSM, BPMC, TLX, ELAN, LNTH, NUVL, CYTK, VRNA, GRFS, and TGTX
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), Cytokinetics (CYTK), Verona Pharma (VRNA), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.
Apogee Therapeutics vs.
Apogee Therapeutics (NASDAQ:APGE) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking.
Apogee Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -74.47%. Apogee Therapeutics' return on equity of -21.81% beat Axsome Therapeutics' return on equity.
Axsome Therapeutics received 445 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 70.25% of users gave Axsome Therapeutics an outperform vote.
Apogee Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 36.1% of Apogee Therapeutics shares are held by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Apogee Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.
Apogee Therapeutics presently has a consensus price target of $89.71, indicating a potential upside of 159.67%. Axsome Therapeutics has a consensus price target of $157.64, indicating a potential upside of 14.44%. Given Apogee Therapeutics' higher probable upside, research analysts plainly believe Apogee Therapeutics is more favorable than Axsome Therapeutics.
In the previous week, Axsome Therapeutics had 54 more articles in the media than Apogee Therapeutics. MarketBeat recorded 55 mentions for Axsome Therapeutics and 1 mentions for Apogee Therapeutics. Axsome Therapeutics' average media sentiment score of 0.44 beat Apogee Therapeutics' score of -0.84 indicating that Axsome Therapeutics is being referred to more favorably in the news media.
Summary
Apogee Therapeutics beats Axsome Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APGE) was last updated on 2/22/2025 by MarketBeat.com Staff
Free APGE Stock Alerts